1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Macular Degeneration – Pipeline Review, H1 2013

Macular Degeneration – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 360 pages

Macular Degeneration – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Macular Degeneration - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Macular Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Macular Degeneration.
- A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Macular Degeneration pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Macular Degeneration - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Macular Degeneration Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Macular Degeneration 13
Macular Degeneration Therapeutics under Development by Companies 15
Macular Degeneration Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Macular Degeneration Therapeutics - Products under Development by Companies 29
Macular Degeneration Therapeutics - Products under Investigation by Universities/Institutes 37
Companies Involved in Macular Degeneration Therapeutics Development 38
Alcon, Inc. 38
Genzyme Corporation 39
Johnson and Johnson 40
F. Hoffmann-La Roche Ltd. 41
Bausch and Lomb Incorporated 42
Allergan, Inc. 43
Shionogi and Co., Ltd. 44
pSivida Corp. 45
Advanced Cell Technology, Inc. 46
GlaxoSmithKline plc 47
Genentech, Inc. 48
Quark Pharmaceuticals, Inc. 49
Lux Biosciences, Inc. 50
Optherion, Inc. 51
RetinaPharma Technologies, Inc. 52
Novartis AG 53
Pfizer Inc. 54
iCo Therapeutics Inc. 55
Lpath, Inc. 56
Mesoblast Ltd 57
BioDiem Ltd 58
ReGenX Biosciences, LLC 59
Circadian Technologies Limited 60
Ophthotech Corp. 61
OXiGENE, Inc. 62
Alexion Pharmaceuticals, Inc. 63
Zenotech Laboratories Limited 64
Regeneron Pharmaceuticals, Inc. 65
NeoStem, Inc. 66
Hanall Pharmaceutical Co., Ltd. 67
Sirion Therapeutics, Inc. 68
Summit Corporation plc 69
ThromboGenics NV 70
PolyMedix, Inc. 71
e-Therapeutics plc 72
NanoCarrier Co., Ltd. 73
R-Tech Ueno, Ltd. 74
Paloma Pharmaceuticals, Inc. 75
Digna Biotech, S.L. 76
Ceregene, Inc. 77
Affitech A/S 78
Ora Bio Ltd. 79
Foamix Ltd. 80
Molecular Partners AG 81
Acucela Inc. 82
Aciont Inc. 83
Neovacs SA 84
Senju Pharmaceutical Co., Ltd. 85
InCode BioPharmaceutics, Inc. 86
OcuCure Therapeutics, Inc. 87
Neurotech Pharmaceuticals, Inc. 88
Gene Signal International SA. 89
Promedior, Inc. 90
Amalyte Pharmaceuticals, LLC 91
Iconic Therapeutics, Inc. 92
Inotek Pharmaceuticals Corporation 93
Indus Biotech Private Limited 94
Cardax Pharmaceuticals, Inc. 95
Intellect Neurosciences, Inc. 96
Omeros Corporation 97
Angstrom Pharmaceuticals, Inc. 98
FirstString Research, Inc. 99
Stemedica Cell Technologies, Inc. 100
Alimera Sciences, Inc. 101
Biovista Inc. 102
Sirnaomics, Inc. 103
Resolvyx Pharmaceuticals, Inc 104
Charlesson LLC. 105
MacuCLEAR, Inc. 106
TRACON Pharmaceuticals, Inc. 107
PanOptica, Inc. 108
OHR Pharmaceutical Inc. 109
Targa Therapeutics Corp. 110
Pfenex Inc. 111
SelectX Pharmaceuticals, Inc. 112
Icon Bioscience, Inc. 113
EyeGene, Inc. 114
Varinel, Inc. 115
Macular Degeneration - Therapeutics Assessment 116
Assessment by Monotherapy Products 116
Assessment by Route of Administration 117
Assessment by Molecule Type 120
Drug Profiles 123
GSK-933776 - Drug Profile 123
volociximab - Drug Profile 124
lampalizumab - Drug Profile 127
ranibizumab - Drug Profile 128
ranibizumab - Drug Profile 131
Lpathomab - Drug Profile 134
iSONEP - Drug Profile 135
emixustat - Drug Profile 137
PMX-20005 - Drug Profile 139
NADPH Oxidase Inhibitor - Drug Profile 140
P-17 - Drug Profile 141
disitertide - Drug Profile 143
unoprostone - Drug Profile 145
AL-78898A - Drug Profile 146
ocriplasmin - Drug Profile 148
Eylea - Drug Profile 151
CERE-140 - Drug Profile 154
ARC-1905 - Drug Profile 155
E-10030 - Drug Profile 157
PARP Inhibitors - Drug Profile 159
INO-6001 - Drug Profile 160
SIR-1076 - Drug Profile 161
SIR-1047 - Drug Profile 162
TKI - Drug Profile 163
AM-1101 - Drug Profile 164
INDUS-815C - Drug Profile 165
NT-501 - Drug Profile 166
TRC-093 - Drug Profile 168
NT-503 - Drug Profile 169
ETX-6201 - Drug Profile 170
bertilimumab - Drug Profile 171
OMS-721 - Drug Profile 173
PF-655 - Drug Profile 175
MC-1101 - Drug Profile 177
MC-1101 - Drug Profile 179
VEGF Kinoid - Drug Profile 181
SAR-402663 - Drug Profile 182
RX-20001 - Drug Profile 183
AL-39324 - Drug Profile 184
PF-04382923 - Drug Profile 185
OC-10X - Drug Profile 186
fluocinolone acetonide - Drug Profile 187
SMT-D004 - Drug Profile 189
CLT-003 - Drug Profile 190
Recombinant Protective Human Complement Factor H Protein - Drug Profile 191
Granzyme B/VEGF - Drug Profile 192
ALXN-1102 - Drug Profile 193
VAR-10200 - Drug Profile 194
TA-106 - Drug Profile 195
A-6 - Drug Profile 196
hI-con1 - Drug Profile 198
aganirsen - Drug Profile 199
P-529 - Drug Profile 201
tandospirone citrate - Drug Profile 204
HC3-1496 - Drug Profile 205
siRNA Micelle - Drug Profile 206
TRC-105 - Drug Profile 207
MP-0112 - Drug Profile 209
PGN-635 - Drug Profile 211
HL-036 - Drug Profile 212
squalamine lactate - Drug Profile 213
IN-N01 - Drug Profile 215
MTP-131 - Drug Profile 216
fosbretabulin disodium - Drug Profile 218
pazopanib hydrochloride - Drug Profile 221
BDM-E - Drug Profile 224
VGX-300 - Drug Profile 226
SIR-1046 - Drug Profile 227
RTU-007 - Drug Profile 228
CNTO-2476 - Drug Profile 229
Retinal Pigment Epithelium (RPE) Program - Drug Profile 231
KH-902 - Drug Profile 233
KH-902 - Drug Profile 235
retinylamine - Drug Profile 237
BVA-301 - Drug Profile 238
ORA-102 - Drug Profile 239
ETX-6991 - Drug Profile 240
Drug For Age Related Macular Degeneration - Drug Profile 241
LX-213 - Drug Profile 242
OpRegen - Drug Profile 243
LFG-316 - Drug Profile 244
bromfenac Adjunct - Drug Profile 245
PRM-167 - Drug Profile 246
Drug For Wet Age Related Macular Degeneration - Drug Profile 247
Mesenchymal Precursor Cells For Macular Degeneration - Drug Profile 248
Drug For Ocular Diseases - Drug Profile 249
STP-601 - Drug Profile 250
VEGF/rGel - Drug Profile 251
XV-615 - Drug Profile 253
PAN-90806 - Drug Profile 254
EG-Mirotin - Drug Profile 256
VSEL for Macular Degeneration and Glaucoma - Drug Profile 258
S-646240 - Drug Profile 259
RST-001 - Drug Profile 260
INO-6002 - Drug Profile 261
EGP-Wet Age Related Macular Degeneration - Drug Profile 262
ranibizumab Biosimilar - Drug Profile 263
NT-506 - Drug Profile 264
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 265
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 266
ARMD Program - Drug Profile 267
IN-N01-OX2 - Drug Profile 268
Anti-Angiogenic Compounds - Drug Profile 269
SNJ-1945 - Drug Profile 270
Cell Migration Inhibitors - Drug Profile 271
Metalloproteinase Inhibitors - Drug Profile 272
PF-05206388 - Drug Profile 273
disitertide Ophthalmic - Drug Profile 274
P-17 Ophthalmic - Drug Profile 275
Age-Related Macular Degeneration Program - Drug Profile 276
OpRegen Plus - Drug Profile 277
RNAi Targeting Vascular Endothelial Growth Factor - Drug Profile 278
KN-014 - Drug Profile 279
RC-1 Alpha - Drug Profile 280
Macular Degeneration Therapeutics - Drug Profile Updates 281
Macular Degeneration Therapeutics - Discontinued Products 335
Macular Degeneration Therapeutics - Dormant Products 336
Macular Degeneration - Product Development Milestones 342
Featured News and Press Releases 342
Appendix 351
Methodology 351
Coverage 351
Secondary Research 351
Primary Research 351
Expert Panel Validation 351
Contact Us 352
Disclaimer 352

List of Tables

Number of Products Under Development for Macular Degeneration, H1 2013 21
Products under Development for Macular Degeneration - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Development by Companies, H1 2013 (Contd..5) 29
Number of Products under Development by Companies, H1 2013 (Contd..6) 30
Number of Products under Investigation by Universities/Institutes, H1 2013 32
Comparative Analysis by Late Stage Development, H1 2013 33
Comparative Analysis by Mid Clinical Stage Development, H1 2013 34
Comparative Analysis by Early Clinical Stage Development, H1 2013 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 36
Products under Development by Companies, H1 2013 37
Products under Development by Companies, H1 2013 (Contd..1) 38
Products under Development by Companies, H1 2013 (Contd..2) 39
Products under Development by Companies, H1 2013 (Contd..3) 40
Products under Development by Companies, H1 2013 (Contd..4) 41
Products under Development by Companies, H1 2013 (Contd..5) 42
Products under Development by Companies, H1 2013 (Contd..6) 43
Products under Development by Companies, H1 2013 (Contd..7) 44
Products under Investigation by Universities/Institutes, H1 2013 45
Alcon, Inc., H1 2013 46
Genzyme Corporation, H1 2013 47
Johnson and Johnson, H1 2013 48
F. Hoffmann-La Roche Ltd., H1 2013 49
Bausch and Lomb Incorporated, H1 2013 50
Allergan, Inc., H1 2013 51
Shionogi and Co., Ltd., H1 2013 52
pSivida Corp., H1 2013 53
Advanced Cell Technology, Inc., H1 2013 54
GlaxoSmithKline plc, H1 2013 55
Genentech, Inc., H1 2013 56
Quark Pharmaceuticals, Inc., H1 2013 57
Lux Biosciences, Inc., H1 2013 58
Optherion, Inc., H1 2013 59
RetinaPharma Technologies, Inc., H1 2013 60
Novartis AG, H1 2013 61
Pfizer Inc., H1 2013 62
iCo Therapeutics Inc., H1 2013 63
Lpath, Inc., H1 2013 64
Mesoblast Ltd, H1 2013 65
BioDiem Ltd, H1 2013 66
ReGenX Biosciences, LLC, H1 2013 67
Circadian Technologies Limited, H1 2013 68
Ophthotech Corp., H1 2013 69
OXiGENE, Inc., H1 2013 70
Alexion Pharmaceuticals, Inc., H1 2013 71
Zenotech Laboratories Limited, H1 2013 72
Regeneron Pharmaceuticals, Inc., H1 2013 73
NeoStem, Inc., H1 2013 74
Hanall Pharmaceutical Co., Ltd., H1 2013 75
Sirion Therapeutics, Inc., H1 2013 76
Summit Corporation plc, H1 2013 77
ThromboGenics NV, H1 2013 78
PolyMedix, Inc., H1 2013 79
e-Therapeutics plc, H1 2013 80
NanoCarrier Co., Ltd., H1 2013 81
R-Tech Ueno, Ltd., H1 2013 82
Paloma Pharmaceuticals, Inc., H1 2013 83
Digna Biotech, S.L., H1 2013 84
Ceregene, Inc., H1 2013 85
Affitech A/S, H1 2013 86
Ora Bio Ltd., H1 2013 87
Foamix Ltd., H1 2013 88
Molecular Partners AG, H1 2013 89
Acucela Inc., H1 2013 90
Aciont Inc., H1 2013 91
Neovacs SA, H1 2013 92
Senju Pharmaceutical Co., Ltd., H1 2013 93
InCode BioPharmaceutics, Inc., H1 2013 94
OcuCure Therapeutics, Inc., H1 2013 95
Neurotech Pharmaceuticals, Inc., H1 2013 96
Gene Signal International SA., H1 2013 97
Promedior, Inc., H1 2013 98
Amalyte Pharmaceuticals, LLC, H1 2013 99
Iconic Therapeutics, Inc., H1 2013 100
Inotek Pharmaceuticals Corporation, H1 2013 101
Indus Biotech Private Limited, H1 2013 102
Cardax Pharmaceuticals, Inc., H1 2013 103
Intellect Neurosciences, Inc., H1 2013 104
Omeros Corporation, H1 2013 105
Angstrom Pharmaceuticals, Inc., H1 2013 106
FirstString Research, Inc., H1 2013 107
Stemedica Cell Technologies, Inc., H1 2013 108
Alimera Sciences, Inc., H1 2013 109
Biovista Inc., H1 2013 110
Sirnaomics, Inc., H1 2013 111
Resolvyx Pharmaceuticals, Inc, H1 2013 112
Charlesson LLC., H1 2013 113
MacuCLEAR, Inc., H1 2013 114
TRACON Pharmaceuticals, Inc., H1 2013 115
PanOptica, Inc., H1 2013 116
OHR Pharmaceutical Inc., H1 2013 117
Targa Therapeutics Corp., H1 2013 118
Pfenex Inc., H1 2013 119
SelectX Pharmaceuticals, Inc., H1 2013 120
Icon Bioscience, Inc., H1 2013 121
EyeGene, Inc., H1 2013 122
Varinel, Inc., H1 2013 123
Assessment by Monotherapy Products, H1 2013 124
Assessment by Stage and Route of Administration, H1 2013 127
Assessment by Stage and Molecule Type, H1 2013 130
Macular Degeneration Therapeutics - Drug Profile Updates 289
Macular Degeneration Therapeutics - Discontinued Products 343
Macular Degeneration Therapeutics - Dormant Products 344
Macular Degeneration Therapeutics - Dormant Products (Contd..1) 345
Macular Degeneration Therapeutics - Dormant Products (Contd..2) 346
Macular Degeneration Therapeutics - Dormant Products (Contd..3) 347
Macular Degeneration Therapeutics - Dormant Products (Contd..4) 348
Macular Degeneration Therapeutics - Dormant Products (Contd..5) 349

List of Figures

Number of Products under Development for Macular Degeneration, H1 2013 21
Products under Development for Macular Degeneration - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 31
Late Stage Products, H1 2013 33
Mid Clinical Stage Products, H1 2013 34
Early Clinical Stage Products, H1 2013 35
Discovery and Pre-Clinical Stage Products, H1 2013 36
Assessment by Monotherapy Products, H1 2013 124
Assessment by Route of Administration, H1 2013 125
Assessment by Stage and Route of Administration, H1 2013 126
Assessment by Molecule Type, H1 2013 128
Assessment by Stage and Molecule Type, H1 2013 129

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016’, provides in depth analysis on Adenosine Recepto ...

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.